Trial Profile
A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2021
Price :
$35
*
At a glance
- Drugs Vixotrigine (Primary)
- Indications Trigeminal neuralgia
- Focus Therapeutic Use
- Sponsors Convergence Pharmaceuticals
- 29 Mar 2021 Results of Population PK model analysis from 12 clinical studies: SCB107718, SCB107727, SCB113210, SCB113210, 802HV101, 802HV102, 802HV104, 802HV105, 802HV106, 802HV107, 1014802/202, 1014802/201 and 1014802/205 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 27 Dec 2018 Recruitment challenges encountered during this study published in the Trials.
- 29 Oct 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.